Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INCEPT intensive care platform trial
NL-OMON59145Phase 4Recruiting
- Sponsor
- Rigshospitalet
- Start
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4 trial of enoxaparin in critical illness, sponsored by Rigshospitalet. Primary endpoint: Domain-specific primary outcome. Started Sep 2026; status: recruiting.
02
Drugs
enoxaparin
03
Conditions
critical illness
Beyond the preview
Go deeper on NL-OMON59145.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59145.